Cannabinoid type 2 receptor agonist JWH-133, attenuates Okadaic acid induced spatial memory impairment and neurodegeneration in rats

Cannabinoid CB2 Receptor Modulation by the Transcription Factor NRF2 is Specific in Microglial Cells

“…Such responses have been also found in post-mortem tissues from patients affected by these diseases (Jordan and Xi 2019). However, it is still unknown what is the molecular mechanism by which CB2 activation has anti-inflammatory effects (Wu et al 2017;Cakir et al 2019). One possibility is that it acts as an inhibitor of the control of proinflammatory cytokines and, as NRF2, promotes the shift from M1 to M2 phenotypes.…”

Adjuvant Cannabinoid Receptor Type 2 Agonist Modulates the Polarization of Microglia Towards a Non-Inflammatory Phenotype in Experimental Pneumococcal Meningitis

“…In vivo, we administered a concentration of JWH-133 (1mg/kg) in line with different models of brain injuries (Murikinati et al, 2010;Gamal et al, 2015;Fujii et al, 2016;Cakir et al, 2019). As previously described, microglia serve as the primary immune cells of the brain, releasing various pro-inflammatory cytokines (Hanisch, 2002).…”

“…It has already been shown to have beneficial effects, including downregulation of the inflammation and the improvement in neurofunctional outcome in different experimental models of brain injury, including okadaic-induced neurodegeneration (Cakir et al, 2019), subarachnoid hemorrhages (Fujii et al, 2014a;Fujii et al, 2014b), stroke (Zarruk et al, 2012;Li et al, 2015;Bravo-Ferrer et al, 2017), endotoxemia (Gamal et al, 2015), traumatic brain injury (Amenta et al, 2014) or Parkinson's disease (Chung et al, 2016).…”

Alzheimer’s Disease Neuroprotection: Associated Receptors

“…Type 2 cannabinoid receptor (CNR2) is overexpressed in activated microglia in different areas of the nervous system. Activated CNR2 has the potential to disrupt the AD process and treat the symptoms, reducing neurodegeneration, neuroinflammation, and improving spatial memory [50]. The role of the type 1 cannabinoid receptor (CNR1) is unclear.…”

“…Cerebral cortex Disrupt the AD process, reduce symptoms, neurodegeneration, neuroinflammation, and improve spatial memory [47][48][49][50].…”